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Abstract: Large randomized controlled clinical trials are the gold standard to evaluate and compare the
effects of treatments. It is common practice for investigators to explore and even attempt to compare
treatments, beyond the first round of primary analyses, for various subsets of the study populations
based on scientific or clinical interests to take advantage of the potentially rich information contained
in the clinical database. Although subjects are randomized to treatment groups in clinical trials, this
does not imply the same degree of randomization among sub-populations of the original trials.
Therefore, comparisons of treatments in sub-populations may not produce fair and unbiased results
without properly addressing this issue. Covariate adjustments in regression analysis and propensity
score matching are commonly used to address the non-randomized nature of the sub-populations issue
with various degrees of success. However, further improvements to these methods are still possible. In
this article, we propose an analysis strategy that shows improvement to conventional methods.
Treatment effects and their differences are estimated after adjustment for background imbalances.
Treatment groups are then compared using confidence intervals whose limits are determined using
the Robbins–Monro stochastic approximation. Data from a recent clinical trial are used to illustrate the
methodology.
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1 Introduction
As stated by Peto et al. [1], “There is simply no serious scientific alternative to the generation of large-
scale randomized evidence. If trials can be vastly simplified, . . ., and thereby made vastly larger, then
they have a central role to play in the development of rational criteria for the planning of health care
throughout the world.” Recruitment of a large number of eligible patients from a general population is
both a major strength and weakness of large pragmatic trials. Deliberately broad and sometimes ill-
defined entry criteria mean that the overall result can be difficult to apply to particular groups. In
modern medical practice, individualized medicine is often advocated, and clinicians frequently need to
make decisions about how best to use results of randomized clinical trials (RCT) and systematic reviews
to maximize the wellbeing of their patients. Therefore, subgroup analyses have become increasingly
necessary, if heterogeneity of treatment effects is likely to occur. However, various views seem to exist
among scientific and clinical communities about the proper justifications and conducts for this kind of
analysis.
Some statisticians and non-clinical epidemiologists have warned about the dangers of subgroup
analyses due to the concerns of multiplicities, data dredging, false positive subgroup treatment effects,
and the rarity of qualitative heterogeneity of relative treatment effect (e.g. see the discussions and references
in Wang et al. [2] and the simulation study by Brookes et al. [3]). On the other hand, groups of practicing
clinicians and statisticians have warned of the dangers of applying the overall results of large trials to
individual patients without consideration of patho-physiology or other determinants of individual response
[4–6]. Rothwell [7] put it in this way.
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The main potential of subgroup analysis is not in the identification of groups that differ in their response to treatment for
reasons of patho-physiology, but is in answering practical questions about how treatments should be used most effectively.
Subgroup analyses related to questions of the practical application of interventions can be vital to effective clinical practice.
In this article, without adding to the debates, we focus on the better methodological conduct of subgroup
data analyses. In practice, sometimes even with stratified randomization specifically for subgroups of
interest, the subgroup data may still have certain degrees of imbalance among some covariates, the
accidental bias as stated by Efron [8] and Lachin [9], which may create bias in data analysis. In general,
smaller trials are more likely to have covariate imbalance; however, imbalance can sometimes also occur in
larger trials. For example, in a post hoc analysis, Wright et al. [10] compared the outcomes in hypertensive
black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril in the trial conducted
by the ALLHAT Collaborative Research Group. Even with the sample size of several thousands in each
stratum, they still showed significant imbalance in several covariates among the strata. Therefore, blindly
analyzing subgroup data without proper adjustment of covariate imbalances may be problematic and even
produce misleading results. Unfortunately, this is not uncommon in medical journals. Our intention in this
article is to bring the matching methods, which had been used quite often in other scientific disciplines, into
clinical trial subgroup data analysis as a tool to better adjust the covariate imbalance. Our simulation study
had shown some remarkable merits of the matching methods for this purpose.
The organization of this manuscript is as follows. In Section 2, we briefly describe the statistical
background of propensity score and the methods of matching to adjust the potential covariate imbalance,
followed by comparisons of their performance in a simulation. In Section 3, we discuss the estimation of
confidence interval of treatment effect using stochastic approximation. An example is provided in Section 4
to illustrate the procedures discussed herein using a data set from a recent clinical trial. Further discussions
are presented in Section 5.
2 Statistical method and notations
The concept of propensity scores is thoroughly discussed by Rosenbaum and Rubin [11] as well as by
other authors. In the following, we describe a few key points for analytical purposes. Let Yi1 denote the
response to the experimental treatment of subject ið1  i  NÞ and Yi0 denote the response to
the control treatment of subject i. Let Xi denote the vector of covariates associated with subject i and
Ti ¼ 1(0), if subject i receives experimental (control) treatment. The observed outcome for subject i is
then Yi ¼ TiYi1 þ ð1 TiÞYi0:
If the subjects were appropriately randomized between experimental treatment and control groups, then
EðYijjTi ¼ 1Þ ¼ EðYijjTi ¼ 0Þ; j ¼ 0; 1;
even though EðYi0jTi ¼ 1Þ of the experimental treatment group and EðYi1jTi ¼ 0Þ of the control group cannot be
estimated from the data since each subject can receive only either experimental or control treatment, but not both.
If the data were appropriately randomized, the estimand of the average treatment effect, which can be
estimated empirically using the observed data, can be written as
τ ¼ EðYi1jTi ¼ 1Þ  EðYi0jTi ¼ 0Þ;
which can be further re-expressed as
:
τ ¼ a1EðYi1jTi ¼ 1Þ  a2EðYi0 jTi ¼ 0Þ þ b1EðYi1 jTi ¼ 1Þ  b2EðYi0 jTi ¼ 0Þ
¼ a1EðYi1 jTi ¼ 1Þ  a2EðYi0 jTi ¼ 1Þ þ b1EðYi1 jTi ¼ 1Þ  b2EðYi0 jTi ¼ 1Þ
¼ a1EðYi1 jTi ¼ 1Þ  a1EðYi0 jTi ¼ 1Þ þ b1EðYi1 jTi ¼ 0Þ  b1EðYi0 jTi ¼ 0Þ
¼ a1½EðYi1 jTi ¼ 1Þ  EðYi0 jTi ¼ 1Þ þ b1½EðYi1 jTi ¼ 0Þ  EðYi0 jTi ¼ 0Þ;
where a1; b1; a2; b2 are all positive with a1 þ b1 ¼ 1, a2 þ b2 ¼ 1, with
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τ1 ¼ ½EðYi1 jTi ¼ 1Þ  EðYi0 jTi ¼ 1Þ and τ0 ¼ ½EðYi1 jTi ¼ 0Þ  EðYi0 jTi ¼ 0Þ
being the (unobserved) treatment effects from the experimental treatment and control groups,
respectively.
When the covariate imbalance occurs, proper matchings of subjects to better balance covariates are
usually recommended in order to obtain a more appropriate estimate of treatment effect. Given covariate Xi
and following the results of Rubin [12, 13], one can show that
EðYij jXi;Ti ¼ 1Þ ¼ EðYij jXi;Ti ¼ 0Þ:
Therefore, the treatment effect of the experimental treatment group
τ1 ¼ EfXi jTi¼1gfEðYi jXi;Ti ¼ 1Þ  EðYi jXi;Ti ¼ 0Þg;
where the expectation is taken over fXi jTi ¼ 1g, can be estimated.
Define the propensity score as
eðXiÞ ¼ PðTi ¼ 1jXiÞ ¼ EðIfTi ¼ 1g jXiÞ;
namely, the probability of patient i being assigned to experimental treatment given the covariate. Assume
ðiÞ 0<PðTi ¼ δi jXiÞ< 1 and ðiiÞPðT1 ¼ δ1; . . . ;TN ¼ δN jX1; . . . ;XNÞ ¼
YN
i¼1
eðXiÞδið1 eðXiÞÞð1δiÞ;
where δi ¼ 0 or 1, Rosenbaum and Rubin [11] showed that
τ1 ¼ EfeðXiÞjTi¼1gfEðYi j eðXiÞ;Ti ¼ 1Þ  EðYi j eðXiÞ;Ti ¼ 0ÞjTi ¼ 1g;
where the expectation is taken over feðXiÞjTi ¼ 1g, and τ0 can be expressed similarly. Therefore, the average
treatment effect can be derived from the estimates of τ1 and τ0. More details about the propensity score can
be found in Rosenbaum [14] in addition to the articles mentioned herein.
Let Xi ¼ ðxi1; xi2; . . . ; xikÞ0 and m  k be the vector of covariates. A common method to estimate eðXiÞ is
via the logit function, i.e.
logitðeðXiÞÞ ¼ β0 þ h1ðη1iÞ þ h2ðη2iÞ; ð1Þ
where h1 and h2 are known functions and
η1i ¼
Xm
r¼1
frðxirÞ and η2i ¼
Xm
r;q¼1
frðxirÞfqðxiqÞ
represent the main effects and interactions, respectively. The parameters in eq. (1) can be estimated using
MLE-based methods. Goodness-of-fit can be checked graphically via, for example, Landwehr et al. [15] or
Tsai [16].
According to Rosenbaum and Rubin [11], it is advantageous to sub-classify or match not only on eðXÞ
but also for other functions of X. In particular, such a refined procedure may be used to obtain estimates of
the average treatment effect in a subpopulation defined by the components of X, for example, gender or
different disease classifications.
In addition to matching by the propensity score defined above, other matching schemes exist. Two of
the more commonly used methods are Mahalanobis and Genetic matching. Given two covariates, Xi and Xj,
the distances between them used in Mahalanobis and Genetic matching are defined as
mdðXi;XjÞ ¼ fðXi  XjÞ0S1ðXi  XjÞg1=2;
and
gmdðXi;XjÞ ¼ fðXi  XjÞ0S1=2WS1=2ðXi  XjÞg1=2;
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respectively, where S1=2 is the Cholesky decomposition of the covariancematrix ofX, andW is a diagonal positive
definite weight matrix. The elements ofW can be chosen objectively to simultaneously minimize the distribu-
tional difference and location difference of covariates between the experimental treatment and control groups
based on the Kolmogorov–Smirnov test and t-test, respectively [17]. On the other hand, W can also be chosen
somewhat subjectively depending on the relative importance among the matched variables. When certain
variables are considered as more important and higher degree of balance for the selected variables is desired,
one can assign higher weights for those variables during the matching processes.
The matching can be performed with either pair-matching or full-matching depends on the
distributions of the data. The treatment effect can then be estimated between the matched data in the
control and experimental groups. The overall treatment effect can be estimated by a weighted average of the
individual matched groups. In the example below, we used the full-matching to estimate the treatment
difference.
The conventional test of covariate balance between groups based on the t-test focuses only on location
and can miss distributional differences between the covariates. On the other hand, the Kolmogorov–
Smirnov test compares distributional differences and can miss differences in locations. By combining
these two tests, matching can often be better assessed.
2.1 Comparison of matching methods via simulation
To further investigate the performance of various matching methods, a simulation with 5,000 iterations was
conducted under various scenarios. Specifically, the simulation plan was designed as follows.
1. Sample size: two sets of sample size were used in simulation. The first set assumes equal sample size
(N ¼ 50; 100; 250; 400; 450; 500) for both experimental treatment and control groups. The second set
also assumes these sample sizes for the experimental treatment group with the control group being
about 20% smaller so that to mimic the different sample size allocations in many RCT and to study the
effect of these methods with different sizes between samples.
2. Assume three covariates (xi1; xi2; and xi3) will be matched between experimental treatment and control
groups. The covariates were assumed to have somewhat different distributions between experimental
treatment and control groups. Four different distributions are assumed. They consist of standard normal
distributions with possibly different means and variances, or contaminated normal distributions with
either symmetric or asymmetric contaminations from either tail. The list of distributions is shown in
Table 1. In a separate simulation, we also include a binary covariate as suggested by a reviewer.
3. The response variable (Y) was assumed to follow two different models. The first model is
Yi ¼ treatment effectþ xi1 þ xi2 þ xi3 þ error;
and the second model is
Yi ¼ treatment effectþ xi1 þ xi2 þ xi3 þ xi1  xi2 þ xi1  xi2 þ xi2  xi3 þ error:
Table 1 Distributions of covariates simulated.
Xi Group F 1 F2 F 3 F4
xi1 Treated Nð0; 1Þ Nð1; 1Þ 0:9Nð1; 1Þ þ 0:1Nð1; 3Þ 0:9Nð1; 1Þ þ 0:1 jNð1; 3Þ j
Control Nð0; 1Þ Nð0; 1Þ 0:9Nð0; 1Þ þ 0:1Nð0; 3Þ 0:9Nð0; 1Þ þ 0:1 jNð0; 3Þ j ð1Þ
xi2 Treated Nð0; 1Þ Nð0; 2Þ 0:9Nð0; 2Þ þ 0:1Nð0; 3Þ 0:9Nð0; 2Þ þ 0:1Nð0; 3Þ
Control Nð0; 1Þ Nð1; 2Þ 0:9Nð1; 2Þ þ 0:1Nð1; 3Þ 0:9Nð1; 2Þ þ 0:1Nð1; 3Þ
xi3 Treated Nð0; 1Þ Nð1; 3Þ 0:9Nð1; 3Þ þ 0:1Nð1; 4Þ 0:9Nð1; 3Þ þ 0:1 jNð1; 4Þ j ð1Þ
Control Nð0; 1Þ Nð0; 3Þ 0:9Nð0; 3Þ þ 0:1Nð0; 4Þ 0:9Nð0; 3Þ þ 0:1 jNð0; 4Þj
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The treatment effect difference between experimental treatment and control groups is assumed to be a
constant, e.g. 1. The purpose of assuming two different models is to compare these methods when the model
is incorrectly specified. These two models were modified accordingly when the binary covariate was
included.
4. The statistical methods to be compared are:
(a) Empirical mean difference,
(b) Least squares (LS) fit (assuming the first model is correct),
(c) LS fit (assuming the second model is correct),
(d) Matching using the propensity score based on xi1; xi2; and xi3;
(e) Matching on xi1; xi2; and xi3 using all available data,
(f) Matching on xi1; xi2; and xi3; and the propensity score using all available data,
(g) Matching on xi1; xi2; and xi3 but excluding data in either tail outside of two times MAD (MAD is
defined as 1:483 medif j xiu medjðxjuÞjg) from the median for each covariate (to mimic Tukey’s
robust trimmed estimate),
(h) Matching on xi1; xi2; and xi3; and the propensity score but excluding data in either tail outside of
two times MAD from the median for each covariate.
5. Two criteria for comparisons are examined:
(a) The estimates of the true treatment effect and the variation of the estimates,
(b) Balancing the covariates between experimental treatment and control groups. This will be
assessed by examining the minimum p-value of the Kolmogorov–Smirnov test for the distribu-
tional equality of each covariate between experimental treatment and control groups before and
after matching. Large p-values indicate greater comparability of the experimental treatment and
control groups in terms of the covariates and hence reflect better covariate balance between
groups.
2.2 Summary of simulation results
By examining the median, the inter-quartile distance, and the overall range of the box plots of the estimated
treatment effects, we make the following conclusions:
1. The simple observed treatment difference can be a very poor estimate when the covariate distributions
are different and deviate from standard normal distributions as shown in Panels 2 and 4 of Figures 1
and 2.
2. For the main effect model, the LS fit (when the model is correctly specified or even over-fitted with
interaction terms) is generally better than other methods in estimating the treatment effect. But the LS
fit with main effect only can perform poorly, if the true model includes interactions; however, the LS fit
with interactions (correct model) outperforms other methods. This finding seems to be quite consistent
among various sample sizes.
3. Matching purely based on propensity scores usually performs worse than Genetic matching either
with all available data or with the trimmed dataset in estimating the true treatment effect. The
trimmed estimate using Genetic matching to match both covariates and propensity scores performs
almost uniformly better than any other method regardless of model specification and sample size,
except for the LS fit when the model is correctly specified as discussed in eq. (2).
4. When the covariates of experimental treatment and control groups have identical normal distribu-
tions, the LS method outperforms all other methods since there is no need for matching. Additional
effort to match seems to be redundant. The propensity score matching seems to make the covariate
matching worse more often than not. However, the Genetic matching seems to perform reasonably
well, especially when the outliers were trimmed away (Panel 1 of Figures 3 and 4).
5. However, when the covariate distributions are different between experimental treatment and control
groups and deviate from the standard normal, the effect of matching from all methods becomes very
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visible. This can be seen in Panels 2–4 of Figures 3 and 4. Genetic matching with trimmed outliers tends
to outperform all other methods either matched only on all covariates or with propensity score
included. This is true for all distributions and sample sizes tested here.
6. The sample size in Figures 1 and 2 was 450, and in Figures 3 and 4, it was 400. The patterns for other
sample sizes are similar with somewhat higher variations for smaller sample sizes, therefore, are not
shown here.
As discussed above, when the model is correctly specified, the simple LS method outperforms other
methods as expected. However, as in most of the data analysis, one rarely knows the correct model or
Panel 1
Panel 3
Panel 2
Panel 4
Figure 1 Estimation of true treatment effect (¼ 1). Panel 1: main effect model with distribution #1 (group labels 1–8 correspond
to methods a–h of Section 2.1). Panel 2: main effect model with distribution #2 (group labels 1–8 correspond to methods a–h of
Section 2.1). Panel 3: main effect model with distribution #3 (group labels 1–8 correspond to methods a–h of Section 2.1). Panel
4: main effect model with distribution #4 (group labels 1–8 correspond to methods a–h of Section 2.1).
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the distribution from which the data was generated. Therefore, the performance of LS method can
sometimes be expected to diminish in the analysis of real data. On the other hand, the performance of
Genetic matching seems to be almost always comparable to the LS method when the model is correctly
specified and performs much better when the model is mis-specified as shown in Panels 1, 2, and 4 of
Figure 2. Therefore, the Genetic matching seems to serve as a “model mis-specification proof” tool for
general data analysis. It is interesting to note that Diamond et al. [18] also similarly concluded that
Genetic matching is preferred over other matching methods, because it is more efficient (smaller MSE)
and is less biased.
Panel 1
Panel 3
Panel 2
Panel 4
Figure 2 Estimation of true treatment effect (¼ 1). Panel 1: main effect and interaction model with distribution #1 (group labels
1–8 correspond to methods a–h of Section 2.1). Panel 2: main effect and interaction model with distribution #2 (group labels 1–
8 correspond to methods a–h of Section 2.1). Panel 3: main effect and interaction model with distribution #3 (group labels 1–8
correspond to methods a–h of Section 2.1). Panel 4: main effect and interaction model with distribution #4 (group label 1–8
correspond to method a–h of Section 2.1).
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3 Estimation of confidence interval of treatment effect
As discussed by Lachin [9] and other researchers, in most clinical trial practices, participants are actually
more of a convenient sample than a truly randomized sample from the intended population with a specific
disease for treatment. After a group of study subjects has been recruited, trialists then give their best efforts
to randomly assign subjects to treatments. That is one of the primary reasons the randomization model is
Panel 1
Panel 3
Panel 2
Panel 4
Figure 3 Minimum p-value of K–S test to compare the equality of covariates. Panel 1: main effect model with distribution #1
(group label 1 is before matching, 2–6 correspond to post-matching of methods d–h of Section 2.1). Panel 2: main effect model
with distribution #2 (group label 1 is before matching, 2–6 correspond to post-matching of methods d–h of Section 2.1). Panel 3:
main effect model with distribution #3 (group label 1 is before matching, 2–6 correspond to post-matching of methods d–h of
Section 2.1). Panel 4: main effect model with distribution #4 (group label 1 is before matching, 2–6 correspond to post-matching
of methods d–h of Section 2.1).
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preferred to the population model by these researchers for statistical inferences. Since subgroups, defined
either pre- or post-randomization, also inherit these properties, randomization model seems to be a natural
choice for inferences.
It is a common statistical practice to accompany the point estimate of treatment effect with the
corresponding confidence interval so that the magnitude of the effect can be better judged by clinical
practitioners. Lachin suggested using randomization model to estimate the treatment effect and invoking
the concept of population model to estimate the confidence interval. As an alternative, one can use the
stochastic approximation as proposed by Robbins and Monro [19] and implemented by Garthwaite [20] to
estimate the confidence interval of the treatment effect. Briefly, for treatment effect θ0, a randomization test
is performed to test the hypothesis H0 : θ ¼ θ0 against both one-sided alternatives H1 : θ < θ0 and H1 : θ > θ0.
Panel 1
Panel 3
Panel 2
Panel 4
Figure 4 Minimum p-value of K–S test to compare the equality of covariates. Panel 1: main effect and interaction model with
distribution #1 (group label 1 is before matching, 2–6 correspond to post-matching of methods d–h of Section 2.1). Panel 2:
main effect and interaction model with distribution #2 (group label 1 is before matching, 2–6 correspond to post-matching of
methods d–h of Section 2.1). Panel 3: main effect and interaction model with distribution #3 (group label 1 is before matching,
2–6 correspond to post-matching of method d–h of Section 2.1). Panel 4: main effect and interaction model with distribution #4
(group label 1 is before matching, 2–6 correspond to post-matching of method d–h of Section 2.1).
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A separate search is performed for each endpoint of the corresponding confidence interval. The upper and
lower endpoints of the confidence interval are updated according to an algorithm after every randomization
test. The asymptotic property of the search process is discussed by Garthwaite and Buckland [21]. In
addition, under weak regularity conditions, the estimates converge in probability to the correct confidence
limits [22].
4 Example
A phase III, multi-national randomized, double blind, placebo-controlled clinical trial was conducted by a
pharmaceutical company to compare the treatment effect of drug A and drug B to placebo in controlling
disease activity in subjects with rheumatoid arthritis having an inadequate clinical response to methotrex-
ate. (Due to the restriction of the data provider, the names of drug A and drug B are not revealed.) The study
was not originally designed to compare drug A and drug B directly. However, a post hoc analysis to
compare these two drugs in a subgroup of countries of the original study is of clinical interest. A total of 156
and 165 patients were randomized to drugs A and B in these countries, respectively. The primary endpoint
of the study was the disease activity score based on 28 joints (DAS28).
Comparisons of several baseline covariates using the t-test did not show particular imbalance between
the two treatment groups. However, a more in-depth investigation of the baseline distributions by quantile–
quantile (Q–Q) plots showed some deviations between the two populations. The objective in this analysis is
to properly estimate the treatment difference under the situation of baseline imbalance.
The first step in this analysis is to match the patients from drugs A and B. Both the propensity score and
the Genetic matching methods were applied with the covariates including age, baseline pain score, baseline
CRP, and other components of DAS28, so that we can compare the relative performance of these two
matching methods. As an example, the baseline pain scores between the treatment groups are compared
and shown in Figure 5. The original Q–Q plot of pain scores between drug A and drug B is shown in Panel 1.
The Q–Q plots of this covariate using propensity score matching and Genetic matching are shown in Panels
2 and 3, respectively. One can clearly see substantial improvement in covariate balance of Genetic matching
over the propensity score matching.
Permutation distributions of the treatment effect before and after Genetic matching were also generated
and are shown in Figure 6. The observed treatment difference prior to matching is about –0.19. However,
the magnitude of the treatment difference was reduced substantially to –0.048 after matching. This
indicates the importance of the proper matching of patients in the two treatment groups. Without this
step, the treatment difference may potentially be over-estimated. Even though the permutation test did not
show a significant treatment difference in either pre- or post-matching, the test prior to matching had a
higher significance level than after matching.
The 95% confidence interval of the treatment effect difference was estimated using the procedure
described previously. A total of 5,000 randomized samples were generated and analyzed. The estimates
fluctuate substantially in the beginning of the approximation process. The process began to stabilize after
about 2,500 randomizations. Figure 7 shows the stochastic approximation for the upper and lower limits of
the confidence interval. The resulting 95% confidence interval is (–0.110, 0.4858).
5 Discussion
Subgroup data analysis is common practice in medical research in order to better understand or explore
treatment effects in different groups of patients. This is an important step toward individualized medicine.
However, how to do it properly to get a more or less unbiased (since no one knows what the truth is)
treatment effect is a difficult task, especially when the data are not appropriately randomized or only
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observational. Researchers have proposed several classes of methods to analyze this kind of data (e.g. see
[23] and the discussions therein) and matching methods, based on propensity score, Mahalanobis matching,
Genetic matching, and their variants, are among the important tools for this purpose. Particularly, Genetic
matching provides the extra flexibility of weighting the selected covariates for the desired matching, so that
the treatment effect estimate can also reflect the preferences of the investigators. With a good matching
between the experimental treatment and control subjects and a higher degree of association between the
covariates and the response, the treatment effect can be more accurately estimated.
In this manuscript, we conducted a simulation to further look into the performance of these methods
under various scenarios with respect to their ability to better balance the covariates between the experi-
mental treatment and control groups and also to produce unbiased estimate of treatment effect. The
methods we compared ranged from the usual linear regression, conventional matching techniques with
all available data to more robust alternatives, which exclude possible outliers. In general, Genetic matching
is preferred to other methods under various data distributions of the covariates and various sample sizes.
Panel 1
Panel 3
Panel 2
Figure 5 Balancing baseline pain score via propensity score and Genetic matching. Panel 1: original Q–Q plot without any
matching. Panel 2: after propensity score matching. Panel 3: after Genetic matching.
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Variable selection to be used in these procedures is an important point to consider. Several authors have
proposed various approaches to incorporate covariates to estimate the propensity score [24–26]. The general
findings are to incorporate variables which are thought to be related to outcomes, and variables thought to
be confounded with both treatment assignment and outcomes. The model which incorporates as many
covariates as possible and the model which includes obvious covariates such as age, gender, and race do
not always seem to perform well. One should note that pre-randomization variables will not be confounded
with treatment assignment in RCT and a successful randomization process is likely to correct for both the
known and the unknown confounders. However, under the scenario of possible missing confounding
variables, known or unknown, compounded with possible covariate imbalance, the performance of
(a) (b)
Figure 7 Stochastic approximation of the 95% confidence interval of treatment effect difference (based on 5,000 simulated
randomizations).
(a) (b)
Figure 6 Comparison of pre- and post-Genetic matching estimates of treatment effects after 5,000 permutation simulations.
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matching methods relative to other approaches is still not well-understood, therefore, it will be further
researched and reported in the future.
It is generally recommended that careful examination of covariate balance between treatment groups be
conducted prior to statistical inferences. Besides the formal test procedures, graphical methods can quite
often reveal the subtle data details which are not easily detected in test procedures. In addition to the
treatment effect estimate, it is more informative to provide readers with a confidence interval that brackets
the estimate, which can be quite useful for the clinicians to gauge the clinical significance of the treatment
effect. Toward this purpose, among other approaches, one can use the Robbins–Monro stochastic approx-
imation to estimate the confidence interval of the treatment effect difference (the R-program is available
from the authors). One may notice that the confidence interval is asymmetric to the estimate in our data
example. The stochastic approximation estimates the upper and lower bounds of the confidence interval
separately by comparing the randomization test statistics using the original and re-randomized data, which
is different from the population model approach. Hence, the asymmetry may be part of the intrinsic
properties of the combination of randomization test and stochastic approximation; however, a more
detailed investigation of this phenomenon seems to be worthwhile.
Toward the goal of individualized medicine, medical research, and practices often use the multi-stage
therapeutic strategies, for example, the dynamic treatment regimes (DTRs), in which dose or treatment is
modified at each stage according to a patient’s current history, disease status, and response to the most
recent treatment in the testing of experimental treatments for serious diseases such as cancer or psychiatric
problems. Statistical research in design and analysis of studies aimed at evaluating the effects of these
strategies also has an active history, for example, Zelen [27] and Wei and Durham [28] on the play-the-
winner rule; Lavori and Dawson [29, 30], Thall et al. [31], Murphy [32], Oetting et al. [33], on the designs of
randomized trials that aim at the evaluation of DTRs; Robins [34–37] on the g-estimation of structural nested
models; and Murphy [38], Robins [39], and Moodie et al. [40] on the optimal treatment regime estimation. As
explained by Moodie et al., the inferences in Robins and Murphy are based on the difference between the
empirical and the counterfactual observations, which is also utilized in our proposed method. Given the
number of treatments in DTRs and the usually moderate number of subjects, their methods utilized the
parametric or semi-parametric method for more efficient estimation and modeling. Even though they could
have employed subject matching as we have done here, the moderate trial size may post a severe limitation.
Alternatively, Zhao et al. [41] proposed a non-parametric individualized treatment rule using outcome
weighting learning which circumvents the need for conditional mean modeling, the counterfactual assump-
tions, and essentially turning the optimal treatment selection into a weighted classification problem using
SVM techniques. Their individual treatment rule assigns treatments to each subject only based on subject’s
prognostic information. Presumably, they could have modified their weighting schemes to increase the
flexibility, as provided by the Genetic matching, to adjust the weights preferred by the investigators beyond
the prognostic factors.
The ultimate goal of these researches is to use the results of the trials as a basis for generating
hypotheses and planning a future, larger scale confirmatory trial, and to tailor the specific treatments for
patient subgroups with specific characteristics in diseases as well as genome and biomarker profiles, so that
potentially better responses can be achieved. As more trials with more subjects have been conducted based
on the best knowledge accumulated from these experimental findings, inevitably, additional questions will
be raised to further identify and compare the patient subgroups with respect to treatment efficacy and
adverse effects. The subgroup analysis method proposed in this article can become an important and handy
tool to perform rigorous post hoc analysis to further understand the inner-workings of the new treatments.
Therefore, the integration of the multi-state therapeutic strategies and careful post hoc subgroup analysis
can become an important effort for medical advancement.
Even though the large-scale randomized controlled trials are generally considered as the gold standard
to generate convincing clinical information, one should not underestimate the importance of subgroup
analysis. One cannot ignore that concerns exist in conducting and reporting subgroup analysis, and
problems persist even with the CONSORT [42] and ICH [43], guidance; however, when properly planned,
K.-T. Tsai and K. Peace: Analysis of Subgroup Data of Clinical Trials 205
Brought to you by | Georgia Southern University
Authenticated
Download Date | 10/24/18 2:38 PM
reported, and interpreted, subgroup analysis can provide valuable information. In some clinical trial
settings, subgroup analysis can also be among the primary objectives. For example, the FDA had
granted marketing approval for Pemetrexed plus Cisplatin [44, 45] to be used to treat non-small cell lung
cancer patients with non-squamous even though the entire study did not show significance in overall
survival.
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